Nature Communications (Dec 2018)
Drug and disease signature integration identifies synergistic combinations in glioblastoma
- Vasileios Stathias,
- Anna M. Jermakowicz,
- Marie E. Maloof,
- Michele Forlin,
- Winston Walters,
- Robert K. Suter,
- Michael A. Durante,
- Sion L. Williams,
- J. William Harbour,
- Claude-Henry Volmar,
- Nicholas J. Lyons,
- Claes Wahlestedt,
- Regina M. Graham,
- Michael E. Ivan,
- Ricardo J. Komotar,
- Jann N. Sarkaria,
- Aravind Subramanian,
- Todd R. Golub,
- Stephan C. Schürer,
- Nagi G. Ayad
Affiliations
- Vasileios Stathias
- Center for Therapeutic Innovation, Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine
- Anna M. Jermakowicz
- Center for Therapeutic Innovation, Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine
- Marie E. Maloof
- Center for Therapeutic Innovation, Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine
- Michele Forlin
- Department of Molecular and Cellular Pharmacology, Center for Computational Science, University of Miami Miller School of Medicine
- Winston Walters
- University of Miami Brain Tumor Initiative, Department of Neurosurgery, University of Miami Miller School of Medicine
- Robert K. Suter
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine
- Michael A. Durante
- Bascom Palmer Eye Institute, Sylvester Comprehensive Cancer Center, Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine
- Sion L. Williams
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine
- J. William Harbour
- Bascom Palmer Eye Institute, Sylvester Comprehensive Cancer Center, Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine
- Claude-Henry Volmar
- Center for Therapeutic Innovation, Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine
- Nicholas J. Lyons
- Broad Institute of Harvard and MIT
- Claes Wahlestedt
- Center for Therapeutic Innovation, Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine
- Regina M. Graham
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine
- Michael E. Ivan
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine
- Ricardo J. Komotar
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine
- Jann N. Sarkaria
- Department of Radiation Oncology, Mayo Clinic
- Aravind Subramanian
- Broad Institute of Harvard and MIT
- Todd R. Golub
- Broad Institute of Harvard and MIT
- Stephan C. Schürer
- Center for Therapeutic Innovation, Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine
- Nagi G. Ayad
- Center for Therapeutic Innovation, Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine
- DOI
- https://doi.org/10.1038/s41467-018-07659-z
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 13
Abstract
Inherent or acquired resistance to treatment of glioblastoma (GBM) is nearly universal. Here, the authors introduce a platform to identify synergistic drug combinations for patient-specific treatment of GBM based on gene expression signatures and small molecule perturbation-response profiles.
